Article
Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.
Clinical and experimental nephrology - 1 Mar 2021
Moriyama Tomofumi, Nakayama Yosuke, Soejima Mikiko, Yokota Yunosuke, Ota Kanji, Ito Sakuya, Kodama Goh, Nakamura Nao, Kurokawa Yuka, Yano Junko, Ueda Utako, Takamiya Yoshimi, Kaida Yusuke, Hazama Takuma, Shibata Ryo, Koda Yoshiro, Fukami Kei
Abstract excerpt
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder caused by mutations in the polycystic kidney disease (PKD) gene. Although tolvaptan has benefits for renal involvement, the different effects depending on the gene mutation type are unknown. Thus, we explore the different effects of tolvaptan on the annual changes in total kidney volume (%TKV) and estimated glomerular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.